ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)
June 14, 2024 08:03 ET
|
Elmedix
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer. Earlier this year, scientists from Columbia University in New...
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
June 10, 2024 08:55 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
Cumulus Oncology Appoints Catherine Lewis La Torre to its Board of Directors
June 10, 2024 04:00 ET
|
Cumulus Oncology
EDINBURGH, Scotland, June 10, 2024 (GLOBE NEWSWIRE) -- Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to...
Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
June 07, 2024 20:18 ET
|
Qu Biologics, Inc.
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...
Premier Diversified Holdings Inc. Announces Entry into Definitive Agreements in Connection with a Reverse Takeover Transaction
June 07, 2024 07:00 ET
|
Premier Diversified Holdings Inc.
Not for dissemination in the United States of America VANCOUVER, British Columbia, June 07, 2024 (GLOBE NEWSWIRE) -- Premier Diversified Holdings Inc. ("PDH" or the "Company") (TSXV:PDH) is pleased...
EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia
June 06, 2024 21:13 ET
|
EnGeneIC
SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has...
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
June 06, 2024 08:30 ET
|
Vaccinex, Inc.
Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
June 06, 2024 08:00 ET
|
Qu Biologics, Inc.
BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
June 03, 2024 09:15 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...